Biotech
Allogene Therapeutics
Allogene Therapeutics raises $325M Series E at $3.9B valuation
$325M
Total Raised
Series E
Latest Round
2017
Founded
700+
Employees
210 East Grand Avenue, South San Francisco, CA 94080
1 min read
Quick Facts
Valuation
$3.9B
Latest Round Size
$325M
Latest Round Date
April 2024
Allogene Therapeutics: Series E Funding Round
Allogene Therapeutics has successfully raised $325M in Series E funding, reaching a valuation of $3.9B.
Company Overview
Allogeneic CAR T therapy developer
Funding Details
The Series E round was led by TPG, with participation from Gilead Sciences, Pfizer, Frazier Healthcare Partners, University of California.
Company Information
- Headquarters: 210 East Grand Avenue, South San Francisco, CA 94080
- Founded: 2017
- Employees: 700+
- Category: Biotech
Investment
Allogene Therapeutics plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- TPG: Verified investor in Series E
- Gilead Sciences: Verified investor in Series E
- Pfizer: Verified investor in Series E
- Frazier Healthcare Partners: Verified investor in Series E
- University of California: Verified investor in Series E
Key Investors
TPG
Lead Investor
Verified investor in Series E
Gilead Sciences
Investor
Verified investor in Series E
Pfizer
Investor
Verified investor in Series E
Frazier Healthcare Partners
Investor
Verified investor in Series E
University of California
Investor
Verified investor in Series E
About the Author
Editorial Team
Curated funding news from verified sources
Related Company Reports
Biotech
Orna Therapeutics
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C
Biotech
Vir Biotechnology
Vir Biotechnology Raises $250M
Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza
Sarah Kim
Oct 23, 2025
0 min read•$250M